tiprankstipranks
Health Canada grants authorization to evaluate MediciNova’s MN-166 in long COVID
The Fly

Health Canada grants authorization to evaluate MediciNova’s MN-166 in long COVID

The company states: "MediciNov announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166, or ibudilast, and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19. The trial, entitled REcovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine, or "RECLAIM," is a collaboration between MediciNova and the University Health Network, the largest hospital-based research program in Canada. MediciNova will supply the study drug and will provide regulatory and safety follow-up support."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on MNOV:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles